Table 2 The distributions of genotypes and alleles of investigated SNPs in prostate cancer patients.
Genotype | n (%) | Alelle (%) | Hardy–Weinberg equilibrium (p value) |
|---|---|---|---|
TGFβ1 C-509T | |||
CC | 45 (52.3%) | C (69.8%) | 0.108 |
CT | 30 (34.9%) | T (30.2%) | |
TT | 11 (12.8%) | ||
TGFβ1 Leu10Pro | |||
LeuLeu | 25 (30.5%) | Leu (56.7%) | 0.538 |
LeuPro | 43 (52.4%) | Pro (43.3%) | |
ProPro | 14 (17.1%) | ||
XRCC1 Arg280His | |||
ArgArg | 81 (97,6%) | Arg (98.8%) | 0.911 |
ArgHis | 2 (2.4%) | His (1.2%) | |
HisHis | 0 (0%) | ||
XRCC3 Thr241Met | |||
ThrThr | 33 (40.7%) | Thr (63.6%) | 0.902 |
ThrMet | 37 (45.7%) | Met (36.4%) | |
MetMet | 11 (13.6%) | ||
